AR029940A1 - Compuestos derivados del ciclopentano, soluciones oftalmicas, soluciones oftalmicas y productos farmaceuticos que incluyen dichos compuestos, uso de los compuestos mencionados para preparar composiciones farmaceuticas para tratar hipertension ocular, y glaucoma - Google Patents
Compuestos derivados del ciclopentano, soluciones oftalmicas, soluciones oftalmicas y productos farmaceuticos que incluyen dichos compuestos, uso de los compuestos mencionados para preparar composiciones farmaceuticas para tratar hipertension ocular, y glaucomaInfo
- Publication number
- AR029940A1 AR029940A1 ARP010102760A ARP010102760A AR029940A1 AR 029940 A1 AR029940 A1 AR 029940A1 AR P010102760 A ARP010102760 A AR P010102760A AR P010102760 A ARP010102760 A AR P010102760A AR 029940 A1 AR029940 A1 AR 029940A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- ophthalmic solutions
- formula
- diseases
- cyclopentane
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000002997 ophthalmic solution Substances 0.000 title abstract 4
- 206010030043 Ocular hypertension Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 abstract 2
- 125000001511 cyclopentyl group Chemical class [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000018083 Bone metabolism disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010021639 Incontinence Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- 230000007365 immunoregulation Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940054534 ophthalmic solution Drugs 0.000 abstract 1
- 230000008085 renal dysfunction Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Se describen y reivindican derivados del ciclopentano de formula (1), donde R es H o COR3, R3 es H , R2, fenilo o COR3, en donde R2 es un grupo alquilo inferior C1-5 y R3 es R2 o fenilo; Z es O o CH2; Y es OH, OCOR3 o O; x es 0 o 1 y X es n-alquilo C1-5, cicloalquilo C3-7, fenilo, furanilo, tienilo o derivados sustituidos de los mismos, donde los sustituyentes se seleccionan del grupo consistente de alquilo C1-5, halogeno, CF3, CN, NO2, NR42, CO2R4 y OR4, en donde R4 es hidrogeno o un grupo alquilo C1-5 y las líneas de puntos representan la presencia o ausencia de un enlace doble y las líneas onduladas corresponden a un enlace cis o un enlace trans. Se reivindican además soluciones oftálmicas que comprenden cantidades terapéuticamente efectivas de un compuesto de formula (1), formulado con un vehículo líquido oftalmologicamente aceptable, no toxico. También se describen y reivindican productos farmacéuticos que comprenden envases adaptados para dispensar el contenido desde el envase en forma medida, donde el contenido del mismo es dicha solucion oftálmica. La presente incluye el uso de los derivados del ciclopentano de formula (1) para preparar composiciones farmacéuticas aplicables en el tratamiento de estados de hipertension ocular o el glaucoma; para tratamientos sistémicos hipertensivos y de enfermedades pulmonares o enfermedades gastrointestinales de la reproduccion, fertilidad, incontinencia, infarto, inmunorregulacion, estados inflamatorios, desordenes del metabolismo oseo, disfunciones renales, cáncer y enfermedades hiperproliferativas, tratamientos que comprenden administrar a mamíferos afectados por una de dichas enfermedades cantidades terapéuticamente efectivas de dichos compuestos de formula (1).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/665,791 US6248783B1 (en) | 2000-09-20 | 2000-09-20 | Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029940A1 true AR029940A1 (es) | 2003-07-23 |
Family
ID=24671590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102760A AR029940A1 (es) | 2000-09-20 | 2001-06-11 | Compuestos derivados del ciclopentano, soluciones oftalmicas, soluciones oftalmicas y productos farmaceuticos que incluyen dichos compuestos, uso de los compuestos mencionados para preparar composiciones farmaceuticas para tratar hipertension ocular, y glaucoma |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6248783B1 (es) |
| EP (1) | EP1318979A1 (es) |
| JP (1) | JP2004511446A (es) |
| AR (1) | AR029940A1 (es) |
| AU (1) | AU2001264891A1 (es) |
| CA (1) | CA2433157A1 (es) |
| WO (1) | WO2002024639A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259010T3 (es) * | 2001-10-26 | 2006-09-16 | Allergan, Inc. | Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep2. |
| KR20050039733A (ko) * | 2001-11-05 | 2005-04-29 | 알러간, 인코포레이티드 | ＥＰ₂-수용체 작용제로서의 ω-시클로알킬 17-헤테로아릴프로스타글란딘 Ｅ₂유사체 |
| US7179820B2 (en) * | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| JP2005511607A (ja) * | 2003-07-10 | 2005-04-28 | アラーガン、インコーポレイテッド | ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体 |
| US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| CN102757459B (zh) * | 2011-04-29 | 2016-01-27 | 上海源力生物技术有限公司 | 用于合成前列腺素类药物的中间体及其制备方法 |
| EP3235810A1 (en) * | 2016-04-19 | 2017-10-25 | Gentec, S.A. | Process for the preparation of bimatoprost |
| CA3132572A1 (en) | 2019-03-27 | 2020-10-01 | Kyowa Pharma Chemical Co., Ltd. | Method for producing pkrostaglandin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1148149A (en) * | 1977-12-08 | 1983-06-14 | Allan Wissner | Prostaglandin activity |
| US4994274A (en) | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| US5034413A (en) | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| CA2021316C (en) | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5028624A (en) | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| EP0825980B1 (en) * | 1995-05-18 | 2001-07-04 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylakenyl derivatives as therapeutic agents for the treatment of ocular hypertension |
| US5741810A (en) * | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
-
2000
- 2000-09-20 US US09/665,791 patent/US6248783B1/en not_active Expired - Fee Related
-
2001
- 2001-05-08 US US09/850,834 patent/US6307092B1/en not_active Expired - Lifetime
- 2001-05-23 AU AU2001264891A patent/AU2001264891A1/en not_active Abandoned
- 2001-05-23 WO PCT/US2001/016770 patent/WO2002024639A1/en not_active Application Discontinuation
- 2001-05-23 EP EP01939364A patent/EP1318979A1/en not_active Withdrawn
- 2001-05-23 JP JP2002529052A patent/JP2004511446A/ja active Pending
- 2001-05-23 CA CA002433157A patent/CA2433157A1/en not_active Abandoned
- 2001-06-11 AR ARP010102760A patent/AR029940A1/es unknown
- 2001-07-26 US US09/915,908 patent/US6359181B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004511446A (ja) | 2004-04-15 |
| US6359181B1 (en) | 2002-03-19 |
| WO2002024639A1 (en) | 2002-03-28 |
| AU2001264891A1 (en) | 2002-04-02 |
| US6307092B1 (en) | 2001-10-23 |
| EP1318979A1 (en) | 2003-06-18 |
| CA2433157A1 (en) | 2002-03-28 |
| US6248783B1 (en) | 2001-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2385267T3 (es) | Utilización de fluprostenol isopropil éster para el tratamiento del glaucoma y de la hipertensión ocular | |
| AR029940A1 (es) | Compuestos derivados del ciclopentano, soluciones oftalmicas, soluciones oftalmicas y productos farmaceuticos que incluyen dichos compuestos, uso de los compuestos mencionados para preparar composiciones farmaceuticas para tratar hipertension ocular, y glaucoma | |
| EA200801245A1 (ru) | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними | |
| MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
| ECSP014097A (es) | Derivados de tiofeno utiles como agentes anticancerosos | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| MA32468B1 (fr) | Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k | |
| JP2006503913A5 (es) | ||
| MA30412B1 (fr) | Composés Pharmaceutiques | |
| DK1257550T3 (da) | Blodplade-ADP-receptor-inhibitor | |
| CA2485850A1 (en) | 8-azaprostaglandin analogs as agents for lowering intraocular pressure | |
| EA200400595A1 (ru) | Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы | |
| CN101838218A (zh) | 酯化合物及其医药用途 | |
| EP2888239B1 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
| JP2023012481A (ja) | 医薬製剤（２） | |
| JP2013035802A (ja) | 緑内障又は高眼圧症の予防又は治療剤 | |
| WO2018159700A1 (ja) | 医薬製剤 | |
| EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
| JP2014502974A5 (es) | ||
| EP2744487B1 (en) | No- and h2s- releasing compounds | |
| JP5302900B2 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
| CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| KR960704876A (ko) | 혈소판 응집 저해 작용을 갖는 신규 화합물 (Novel Compound Having Platelet Aggregation Inhibitor Effect) | |
| JP2022160467A (ja) | 医薬品（２） | |
| ATE415395T1 (de) | Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |